Blog Voices from the Frontlines
One in 12 doctors accepts payment from pharmaceutical companies related to opioids - Americans for Safe Access
One in twelve physicians - and nearly one in five family medicine physicians - accepted payments from pharmaceutical companies related to opioids, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine. This is the first large-scale, national study of industry payments involving opioids and suggests that pharmaceutical companies may have a stronger hold than previously known on how doctors prescribe the powerful drugs.
Update 9/8/2017- Congress has approved a continuing resolution to keep the government open through December 8th, 2017. In addition to funding government agencies this continuing resolution also maintains that the Department of Justice can not use funds to prevent the implementation of a medical cannabis program or to prosecute patients. The continuing resolution extends the time for negotiations of the 2018 fiscal year budget. If the continuing resolution is signed by President Trump, this means that protections for medical cannabis patients will continue through December 8th. Under the previous continuing resolution, patient protections were set to expire on September 30th without Congressional action.
Unfortunately, the House Rules Committee blocked amendments related to medical cannabis from being voted on as part of the 2018 Appropriations process. Despite this setback in the House, protections for patients have been approved in the Senate version of the Appropriations bill. In the coming weeks, there will be a meeting of a conference committee which will resolve the differences between the Senate and House appropriations bills. We hope that the conference committee listens to millions of Americans who support the use of cannabis as medicine and include patient protections in the final bill they send to President Trump.
In addition to the pushing the conference committee to include patient protections, as always we will continue to work diligently to pass permanent legislation like the CARERS act to ensure patients are not made into criminals.
Letter: Medical cannabis can be a lifeline for those suffering from severe pain - Americans for Safe Access
Our nation’s addiction to opioids has been building for 10 years and Illinois’ failed medical cannabis policies compound this problem, putting our patients at a dangerous and potentially deadly disadvantage. The Tribune reported on President Donald Trump’s declaration labeling the opioid epidemic a national emergency. As a seasoned orthopedic surgeon, I can attest to the devastating effects opioid dependency has on my patients, their families and friends, and our society as a whole. It is a critical public safety issue that must be addressed immediately.
On Thursday, August 10th, President Donald Trump told reporters that “the opioid crisis is an emergency…a national emergency.” President Trump is correct: the United States is in the middle of an opioid epidemic. From 1999-2015, over 183,000 Americans died from prescription-opioid overdoses. More worrisome than the total number of overdoses is that opioid overdoses have quadrupled since 1999, resulting in 33,091 deaths in 2015, with 16,000 alone from prescription opioid pain relievers.
On Monday, August 14th, Maryland’s Medical Cannabis Commission announced the approval of three PFC-certified companies to grow and process medical cannabis for the patients of Maryland who have waited so long. Along with ForwardGro, the first company to receive a Stage 2 license in Maryland, Freestate Wellness, Harvest of Maryland, and Green Leaf Medical are currently part of ASA’s Patient Focused Certification program.
By Joanne Cachapero for MG Magazine
Marijuana advocacy organization Americans for Safe Access warns the struggle is real.
Americans for Safe Access Executive Director Steph Sherer has the chops of someone who’s been an advocate for a long time—fifteen years so far, and no stopping is in sight for her or the organization. Based in Washington, D.C., ASA lobbies and advocates on behalf of medical marijuana patients, cultivators, manufacturers, and retailers.
There’s never a dull moment in the American capital, according to Sherer, especially under the current administration. “I think the cannabis industry has two amazing things going for it right now that have nothing to do with [the White House],” she said, laughing.
It's hard to go a day in Canada without hearing about at least one of two types of drugs – but for vastly different reasons. One class of drug—opioids —kills four people a day in British Columbia. The other —cannabis —will be legal for adult purchase and consumption by this time next year.
In the August 2017 Issue
- Senate Committee Passes Measure Protecting Patients
- Veterans Rights Amendment Clears Senate Committee
- ASA and Federal Task Force Urge Respect for State Programs
- PFC Offers Free Services for Laboratories, new webinars, podcasts
- Massachusetts Medical Society Promotes Cannabis Education
- ASA Activist Profile: Jill K. Swing, Charleston, South Carolina
- ACTION ALERT: Contact Your Congressional Reps
Can marijuana save the day? Not yet. But Americans in pain are already turning to the marijuana plant.
The hope: One day you’ll have a choice of varieties or formulations of compounds in marijuana — called “cannabinoids” — that bring relief, aren’t addictive, and leave your mind clear.